Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AZD6482 + Rucaparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD6482||KIN-193|AZD-6482||PIK3CB inhibitor 8 PIK3CD inhibitor 26||AZD6482 inhibits PIK3CB and PIK3CD, preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival (PMID: 24992874, PMID: 23674493, PMID: 31292159, PMID: 30542720).|
|Rucaparib||Rubraca||AG014699|PF-01367338|CO-388|AG14447||PARP Inhibitor (Pan) 26||Rubraca (rucaparib) binds to and inhibits PARP, which may result in accumulation of DNA damage and chemosensitization of tumor cells (PMID: 17363489). Rubraca (rucaparib) is FDA approved for use as a maintenance therapy in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, for treatment in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring deleterious somatic and/or germline BRCA mutations who received 2 or more chemotherapies, and in patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer who received anti-androgen therapy and a taxane-based therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PTEN loss||triple-receptor negative breast cancer||sensitive||AZD6482 + Rucaparib||Preclinical - Cell culture||Actionable||In a preclinical study, the combination of Rubraca (rucaparib) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|